SCHEMBL27192016

SCHEMBL27192016

COc1cc(B(O)O)c(Cl)cc1C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.41
KMT2A Q03164 4/20 0.37
MAPT P10636 4/20 0.37
MEN1 O00255 3/20 0.37
ALDH1A1 P00352 3/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ORAI1 Q96D31 1/20 0.35
ORAI2 Q96SN7 1/20 0.35
ORAI3 Q9BRQ5 1/20 0.35
GAA P10253 1/20 0.35
NPC1 O15118 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
ALOX15 P16050 1/20 0.34
GLA P06280 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5633312 0.92 ENPP2 (0.41) ENPP2KMT2AMAPTMEN1ALDH1A1
SCHEMBL29955855 0.92 ENPP2 (0.41) ENPP2KMT2AMAPTMEN1ALDH1A1
SCHEMBL30905973 0.85 ENPP2 (0.45) ENPP2KMT2AMAPTMEN1ALDH1A1
SCHEMBL2567303 0.85 ENPP2 (0.45) ENPP2KMT2AMAPTMEN1ALDH1A1
SCHEMBL29517531 0.83 NPC1 (0.52) ENPP2KMT2AMAPTMEN1ALDH1A1
SCHEMBL3576560 0.83 NPC1 (0.52) ENPP2KMT2AMAPTMEN1ALDH1A1
SCHEMBL23406340 0.81 ENPP2 (0.45) ENPP2KMT2AMAPTMEN1L3MBTL1
SCHEMBL30905960 0.81 ENPP2 (0.45) ENPP2KMT2AMAPTMEN1ALDH1A1
SCHEMBL29952863 0.79 GAA (0.47) ENPP2KMT2AMAPTALDH1A1GAA
SCHEMBL15757679 0.79 GAA (0.47) ENPP2KMT2AMAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410183-B2 Sars-cov2 main protease inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 US disclosed
US-20250042915-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2025-02-06 US disclosed
US-12091420-B2 SARS-COV2 main protease inhibitors GILEAD SCIENCES, INC. (US) 2024-09-17 US disclosed
US-20240239807-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2024-07-18 US disclosed
US-20240116946-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2024-04-11 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042915-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE ENPP2 715/4885KMT2A 3085/4885MAPT 2197/4885
US-12091420-B2 SARS-COV2 main protease inhibitors ACE2, TMPRSS2, ACE ENPP2 715/4885KMT2A 3085/4885MAPT 2197/4885
US-20240116946-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE ENPP2 715/4885KMT2A 3085/4885MAPT 2197/4885
US-12410183-B2 Sars-cov2 main protease inhibitors ACE2, TMPRSS2, ACE ENPP2 715/4885KMT2A 3085/4885MAPT 2197/4885
US-20240239807-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE ENPP2 715/4885KMT2A 3085/4885MAPT 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.